Bob Bradway, Amgen CEO (Justin Kase Conder/AP Images for Amgen)

Am­gen chief Brad­way nabs a rare dis­ease play­er in $4B buy­out as the M&A tem­po ac­cel­er­ates

Am­gen CEO Bob Brad­way is bel­ly­ing up to the M&A ta­ble to­day, scoop­ing up the new­ly anoint­ed com­mer­cial biotech Chemo­Cen­tryx $CCXI and its re­cent­ly ap­proved rare dis­ease drug for $3.7 bil­lion out of the cash stock­pile. The deal comes in at $52 a share — a hefty in­crease over the $24.11 close yes­ter­day.

Brad­way and the Am­gen team get a drug called Tavneos (ava­co­pan) in the deal, a com­ple­ment fac­tor C5a in­hibitor OK’d to treat an­ti-neu­trophil cy­to­plas­mic au­toan­ti­body (AN­CA)-vas­culi­tis, an au­toim­mune dis­ease which can be lethal.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters